AIM-quoted refugee from the Full List, Amberley Group, the former speciality mineral and chemical outfit now a shell company run by French entrepreneur Guy Naggar, lost £68,000 in the six months to October and is continuing to 'search for opportunities to create significant shareholder value in the long term'. Robert Tyerman reports.
Amberley, which raised £1 million at 10p plus warrants in August, says its net asset value at the end of October was £2.45 million, or 6.95p a share, including £2.3 million cash. In late October, the company bought contracts for difference over ten million shares in fully listed fibres, umbrellas and wall coverings group Chapelthorpe at an average price of 18.9p a share, against today's 20p.
Naggar says Amberley has looked at 'a number of potential investments, in both the public and private arena' and promises that 'shareholders will be kept informed of any major developments'. Positive news would be welcome indeed for investors who have seen the shares halve to 12p since 2000.
Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. You can purchase the directory at the pre-order price with a 15% saving (+VAT). Offer valid until 15th September 2015. Order your copy today.
The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info
Latest small-cap and growth company news
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Technological innovations have seriously helped reshape the way in which we interact with the world and the people around us. And the smartphone has become a one-stop device for communication, travel, online browsing, taking photos, watching videos and even high-definition gaming.
Shares in clinical research organisation Venn Life Sciences are up around 5 per cent at the time of writing following the company's positive trading update ahead of its results announcement for the first half of the year on 22 September.